Top 10 acir.org Competitors

cancergrandchallenges.org

Taking place on 1 - 3 September 2026 in London, UK. Registration opens 5 January 2026.

friendsofcancerresearch.org

Contact Friends of Cancer Research with your question, comment, or inquiry.

multiplemyelomahub.com

Stay up to date with the latest medical news in Multiple Myeloma Hub by receiving trial data, therapy approvals, expert opinions, and more direct to your inbox. Sign up now!

pancan.org

We're the national organization providing support, resources, volunteer opportunities and hope for people fighting pancreatic cancer.

cellandgene.com

Stay ahead in the rapidly evolving field of siRNA therapeutics by exploring the latest clinical trends, breakthrough delivery technologies, combination strategies, and global regulatory pathways.

jitc.biomedcentral.com

Background Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of particular relevance in hepatocellular carcinoma (HCC). Autologous chimeric antigen receptor (CAR) αβ T cell therapies have established significant clinical benefit in hematologic malignancies, although efficacy in solid tumors has been limited due to several challenges including T cell homing, target antigen heterogeneity, and immunosuppressive tumor microenvironments. Gamma delta (γδ) T cells are highly cytolytic effectors that can recognize and kill tumor cells through major histocompatibility complex (MHC)-independent antigens upregulated under stress. The Vδ1 subset is preferentially localized in peripheral tissue and engineering with CARs to further enhance intrinsic antitumor activity represents an attractive approach to overcome challenges for conventional T cell therapies in solid tumors. Allogeneic Vδ1 CAR T cell therapy may also overcome other hurdles faced by allogeneic αβ T cell therapy, including graft-versus-host disease (GvHD).Methods We developed the first example of allogeneic CAR Vδ1 T cells that have been expanded from peripheral blood mononuclear cells (PBMCs) and genetically modified to express a 4-1BB/CD3z CAR against GPC-3. The CAR construct (GPC-3.CAR/secreted interleukin-15 (sIL)-15) additionally encodes a constitutively-secreted form of IL-15, which we hypothesized could sustain proliferation and antitumor activity of intratumoral Vδ1 T cells expressing GPC-3.CAR.Results GPC-3.CAR/sIL-15 Vδ1 T cells expanded from PBMCs on average 20,000-fold and routinely reached >80% purity. Expanded Vδ1 T cells showed a primarily naïve-like memory phenotype with limited exhaustion marker expression and displayed robust in vitro proliferation, cytokine production, and cytotoxic activity against HCC cell lines expressing low (PLC/PRF/5) and high (HepG2) GPC-3 levels. In a s

esmoiotech.org

immuno-oncology technology, immuno oncology technology, iotech

biolegend.com

Find resources to help use our products including our concentration lookup tool, documentation, protocols, and answers to commonly asked questions.

horizoncme.com

Advanced Practice Providers Oncology Summit ABOUT APPOS Planned With and for Advanced Practice Providers in Oncology The APP Oncology Summit is an annual two-day conference designed to provide advanced practice providers (APPs) with the latest evidence-based strategies to optimize care and outcomes for patients with cancer. This conference is planned with and for advanced practice […]